Clinical trial registry record

Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 16, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06683950
Last registry update
July 16, 2026
Status
Completed
Phase
Phase 4
Sponsor
Kim's Eye Hospital
Enrollment
35
Countries
South Korea
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
35
Population
ALL · 50 Years
Duration
2024-10-21 to 2026-07-14
Intervention
Aflibercept 8mg
Comparator
Not reported
Outcomes measured
Presence of retinal fluid — Between 8 - 16 weeks (At the same interval as the previous dosing schedule for aflibercept…; Change in best-corrected visual acuity (BCVA) — Between 8 - 16 weeks (At the same interval as the previous dosing sched…; Change in central retinal thickness (CRT) — Between 8 - 16 weeks (At the same interval as the previous dosing schedule…; Change in subfoveal choroidal thickness (SCT) — Between 8 - 16 weeks (At the same interval as the previous dosing sched…; Change in the size of neovascularization — Between 8 - 16 weeks (At the same interval as the previous dosing schedule f…; Maximum fluid-free period — Between 8 - 16 weeks (At the same interval as the previous dosing schedule for aflibercept…; The proportion of eyes exhibiting fluid — Between 8 - 16 weeks (At the same interval as the previous dosing schedule fo…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON